

ABOUT THE EDITORS

Hanny Al-Samkari, MD, Executive Editor, is an associate professor of medicine at Harvard Medical School. He is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital, where he practices adult classical hematology and directs the Massachusetts General Hospital Hereditary Hemorrhagic Telangiectasia Center of Excellence. His research focuses on the development of novel therapeutics in hereditary hemorrhagic telangiectasia, immune thrombocytopenia, and congenital red cell disorders. He additionally does research on the alleviation of hematologic adverse effects of cancer treatment.

Alison R. Walker, MD, MPH, MBA, Deputy Editor, is a professor of oncologic sciences at the University of South Florida and a member of the Department of Malignant Hematology at H. Lee Moffitt Cancer Center & Research Institute, where she serves as chief of the Medical Oncology Service Line and is the physician practice advisor to the Moffitt Medical Group. Dr. Walker's clinical and research interests are in the care of patients with myeloid malignancies, specifically acute myeloid leukemia and myelodysplastic syndromes.

Rakhi P. Naik, MD, MHS, Deputy Editor, is an associate professor of medicine at Johns Hopkins University, where she serves as clinical director of the Division of Hematology and associate program director for the Hematology Fellowship Track. Dr. Naik's research focuses on sickle cell disease, sickle cell trait, and medical education innovation.

Alex F. Herrera, MD, Deputy Editor, is an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California. His clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with Hodgkin or non-Hodgkin lymphomas. He also studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation with the goal of designing biomarker-based clinical trials to improve outcomes and personalize lymphoma treatment.

Ang Li, MD, MS, Special Section Editor, is an assistant professor at Baylor College of Medicine, a member of the Dan L Duncan Comprehensive Cancer Center, and a Cancer Prevention & Research Institute of Texas (CPRIT) Scholar. Clinically, he specializes in the care of patients with thrombotic and bleeding disorders. As a physician-scientist, he focuses on the epidemiology, prevention, and treatment of venous thromboembolism and thrombotic microangiopathy in association with cancer treatment and hematopoietic cell transplantation.



The American Society of Hematology
2021 L Street, NW
Suite 900
Washington, DC 20036

Hematology 2023: the American Society of Hematology Education Program is supported by educational grants from AstraZeneca, Incyte Corporation, Jazz Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation